Chemopreventive apigenin controls UVB-induced cutaneous proliferation and angiogenesis through HuR and thrombospondin-1

Plant flavonoid apigenin prevents and inhibits UVB-induced carcinogenesis in the skin and has strong anti-proliferative and anti-angiogenic properties. Here we identify mechanisms, by which apigenin controls these oncogenic events. We show that apigenin acts, at least in part, via endogenous angiogenesis inhibitor, thrombospondin-1 (TSP1). TSP1 expression by the epidermal keratinocytes is potently inhibited by UVB. It inhibits cutaneous angiogenesis and UVB-induced carcinogenesis. We show that apigenin restores TSP1 in epidermal keratinocytes subjected to UVB and normalizes proliferation and angiogenesis in UVB-exposed skin. Importantly, reconstituting TSP1 anti-angiogenic function in UVB-irradiated skin with a short bioactive peptide mimetic representing exclusively its anti-angiogenic domain reproduced the anti-proliferative and anti-angiogenic effects of apigenin. Cox-2 and HIF-1α are important mediators of angiogenesis. Both apigenin and TSP1 peptide mimetic attenuated their induction by UVB. Finally we identified the molecular mechanism, whereby apigenin did not affect TSP1 mRNA, but increased de novo protein synthesis. Knockdown studies implicated the RNA-binding protein HuR, which controls mRNA stability and translation. Apigenin increased HuR cytoplasmic localization and physical association with TSP1 mRNA causing de novo TSP1 synthesis. HuR cytoplasmic localization was, in turn, dependent on CHK2 kinase. Together, our data provide a new mechanism, by which apigenin controls UVB-induced carcinogenesis.

[1]  A. Serafin,et al.  Effects of potassium apigenin and verbena extract on the wound healing process of SKH‐1 mouse skin , 2014, International wound journal.

[2]  R. Weinberg,et al.  Thrombospondin-1 repression is mediated via distinct mechanisms in fibroblasts and epithelial cells , 2014, Oncogene.

[3]  M. Gaestel,et al.  The role of mammalian MAPK signaling in regulation of cytokine mRNA stability and translation. , 2014, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[4]  S. Srikantan,et al.  Tyrosine phosphorylation of HuR by JAK3 triggers dissociation and degradation of HuR target mRNAs , 2013, Nucleic acids research.

[5]  H. Mukhtar,et al.  MicroRNAs in skin response to UV radiation. , 2013, Current drug targets.

[6]  J. Pelling,et al.  Targeting the PI3K/Akt/mTOR axis by apigenin for cancer prevention. , 2013, Anti-cancer agents in medicinal chemistry.

[7]  Jun Wang,et al.  Multiple Functions of the RNA-Binding Protein HuR in Cancer Progression, Treatment Responses and Prognosis , 2013, International journal of molecular sciences.

[8]  G. Halliday,et al.  Non-melanoma skin cancer: carcinogenesis and chemoprevention , 2013, Pathology.

[9]  T. Miki,et al.  Apigenin Sensitizes Prostate Cancer Cells to Apo2L/TRAIL by Targeting Adenine Nucleotide Translocase-2 , 2013, PloS one.

[10]  J. Keene,et al.  Mechanisms coordinating ELAV/Hu mRNA regulons. , 2013, Current opinion in genetics & development.

[11]  E. Y. Kim,et al.  Sub-toxic dose of apigenin sensitizes HepG2 cells to TRAIL through ERK-dependent up-regulation of TRAIL receptor DR5 , 2013, Molecules and cells.

[12]  A. Guialis,et al.  HuR–hnRNP interactions and the effect of cellular stress , 2012, Molecular and Cellular Biochemistry.

[13]  J. Henkin,et al.  Prospective study of thrombospondin-1 mimetic peptides, ABT-510 and ABT-898, in dogs with soft tissue sarcoma. , 2012, Journal of veterinary internal medicine.

[14]  R. Béliveau,et al.  Diet-derived polyphenols inhibit angiogenesis by modulating the interleukin-6/STAT3 pathway. , 2012, Experimental cell research.

[15]  V. Bours,et al.  Casein kinase 2 inhibition modulates the DNA damage response but fails to radiosensitize malignant glioma cells. , 2012, International journal of oncology.

[16]  C. Tayade,et al.  Thrombospondin-1 mimetic peptide ABT-898 affects neovascularization and survival of human endometriotic lesions in a mouse model. , 2012, The American journal of pathology.

[17]  K. Kajiya,et al.  Ultraviolet light‐induced changes of lymphatic and blood vasculature in skin and their molecular mechanisms , 2012, Experimental dermatology.

[18]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[19]  J. Pelling,et al.  Apigenin, a chemopreventive bioflavonoid, induces AMP‐activated protein kinase activation in human keratinocytes , 2012, Molecular carcinogenesis.

[20]  O. Volpert,et al.  Therapies using anti-angiogenic peptide mimetics of thrombospondin-1 , 2011, Expert opinion on therapeutic targets.

[21]  J. Henkin,et al.  ABT-898 Induces Tumor Regression and Prolongs Survival in a Mouse Model of Epithelial Ovarian Cancer , 2011, Molecular Cancer Therapeutics.

[22]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[23]  J. Henkin,et al.  A thrombospondin-mimetic peptide, ABT-898, suppresses angiogenesis and promotes follicular atresia in pre- and early-antral follicles in vivo. , 2010, Endocrinology.

[24]  E. Ansó,et al.  Flavonoids inhibit hypoxia-induced vascular endothelial growth factor expression by a HIF-1 independent mechanism. , 2010, Biochemical pharmacology.

[25]  Laura E. Pascal,et al.  Tumor suppressor U19/EAF2 regulates thrombospondin-1 expression via p53 , 2009, Oncogene.

[26]  M. Weichenthal,et al.  The angiogenesis inhibitor thrombospondin-1 inhibits acute cutaneous hypersensitivity reactions. , 2009, The Journal of investigative dermatology.

[27]  S. Srikantan,et al.  Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype , 2008, Oncogene.

[28]  J. Pelling,et al.  Inhibition of HIF‐1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3‐M cells , 2008, Molecular carcinogenesis.

[29]  J. Lawler,et al.  Thrombospondins: from structure to therapeutics , 2008, Cellular and Molecular Life Sciences.

[30]  B. Wienecke,et al.  Apigenin‐induced nitric oxide production involves calcium‐activated potassium channels and is responsible for antiangiogenic effects , 2007, Journal of thrombosis and haemostasis : JTH.

[31]  M. Resnick,et al.  Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. , 2007, Cancer research.

[32]  X. Hong,et al.  Modulation of UVB‐induced and basal cyclooxygenase‐2 (COX‐2) expression by apigenin in mouse keratinocytes: Role of USF transcription factors , 2007, Molecular carcinogenesis.

[33]  G. Chiou,et al.  Apigenin inhibits laser-induced choroidal neovascularization and regulates endothelial cell function. , 2006, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[34]  J. Pelling,et al.  Apigenin Prevents UVB-Induced Cyclooxygenase 2 Expression: Coupled mRNA Stabilization and Translational Inhibition , 2006, Molecular and Cellular Biology.

[35]  Xianglin Shi,et al.  Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. , 2006, Carcinogenesis.

[36]  A. Kong,et al.  Modulation of activator protein-1 (AP-1) and MAPK pathway by flavonoids in human prostate cancer PC3 cells , 2006, Archives of pharmacal research.

[37]  G. Boccaccio,et al.  Mammalian Smaug Is a Translational Repressor That Forms Cytoplasmic Foci Similar to Stress Granules* , 2005, Journal of Biological Chemistry.

[38]  X. Hong,et al.  Inhibition of TPA‐induced cyclooxygenase‐2 (COX‐2) expression by apigenin through downregulation of Akt signal transduction in human keratinocytes , 2005, Molecular carcinogenesis.

[39]  Xianglin Shi,et al.  Apigenin Inhibits Expression of Vascular Endothelial Growth Factor and Angiogenesis in Human Lung Cancer Cells: Implication of Chemoprevention of Lung Cancer , 2005, Molecular Pharmacology.

[40]  Bing-Hua Jiang,et al.  Apigenin inhibits VEGF and HIF‐1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  M. Detmar,et al.  Ultraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin‐1 , 2005, The British journal of dermatology.

[42]  M. Detmar,et al.  Tumor progression: the effects of thrombospondin-1 and -2. , 2004, The international journal of biochemistry & cell biology.

[43]  G. T. Bowden,et al.  UVA-mediated activation of signaling pathways involved in skin tumor promotion and progression. , 2004, Seminars in cancer biology.

[44]  E. Rofstad,et al.  Thrombospondin-1 treatment prevents growth of dormant lung micrometastases after surgical resection and curative radiation therapy of the primary tumor in human melanoma xenografts. , 2004, International journal of radiation oncology, biology, physics.

[45]  Yue Xue,et al.  The chemopreventive bioflavonoid apigenin modulates signal transduction pathways in keratinocyte and colon carcinoma cell lines. , 2003, The Journal of nutrition.

[46]  P. Bornstein,et al.  Restoration of thrombospondin 1 expression in tumor cells harbouring mutant ras oncogene by treatment with low doses of doxycycline. , 2003, Biochemical and biophysical research communications.

[47]  Myoung H. Kim Flavonoids inhibit VEGF/bFGF‐induced angiogenesis in vitro by inhibiting the matrix‐degrading proteases , 2003, Journal of cellular biochemistry.

[48]  J. Redondo,et al.  Cyclooxygenase-2: a therapeutic target in angiogenesis. , 2003, Trends in molecular medicine.

[49]  M. Detmar,et al.  Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice , 2002, Oncogene.

[50]  M. Detmar,et al.  Targeted overexpression of the angiogenesis inhibitor thrombospondin-1 in the epidermis of transgenic mice prevents ultraviolet-B-induced angiogenesis and cutaneous photo-damage. , 2002, The Journal of investigative dermatology.

[51]  J. Lawler,et al.  Thrombospondin‐1 as an endogenous inhibitor of angiogenesis and tumor growth , 2002, Journal of cellular and molecular medicine.

[52]  G. T. Bowden,et al.  Role of p38 MAP kinases and ERK in mediating ultraviolet-B induced cyclooxygenase-2 gene expression in human keratinocytes , 2001, Oncogene.

[53]  H. Inoue,et al.  Roles of Akt and glycogen synthase kinase 3beta in the ultraviolet B induction of cyclooxygenase-2 transcription in human keratinocytes. , 2001, Cancer research.

[54]  M. Detmar The role of VEGF and thrombospondins in skin angiogenesis. , 2000, Journal of dermatological science.

[55]  M. Detmar,et al.  Thrombospondin‐1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice , 2000, The EMBO journal.

[56]  H. Xiao,et al.  Increase in wild-type p53 stability and transactivational activity by the chemopreventive agent apigenin in keratinocytes. , 2000, Carcinogenesis.

[57]  E. Fosslien Biochemistry of Cyclooxygenase (COX)-2 Inhibitors and Molecular Pathology of COX-2 in Neoplasia , 2000, Critical reviews in clinical laboratory sciences.

[58]  M. Skobe,et al.  Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. , 1999, The American journal of pathology.

[59]  R. Hynes,et al.  Thrombospondin-1 Is a Major Activator of TGF-β1 In Vivo , 1998, Cell.

[60]  J. Pelling,et al.  Induction of p21/WAF1 and G1 cell‐cycle arrest by the chemopreventive agent apigenin , 1997, Molecular carcinogenesis.

[61]  P. Pour,et al.  Inhibition of ultraviolet light induced skin carcinogenesis in SKH-1 mice by apigenin, a plant flavonoid. , 1997, Anticancer research.

[62]  B. Li,et al.  The chemopreventive flavonoid apigenin induces G2/M arrest in keratinocytes. , 1996, Carcinogenesis.

[63]  D. Roberts,et al.  Regulation of tumor growth and metastasis by thrombospondin‐1 , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[64]  K. Dameron,et al.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.

[65]  M. L. Le Beau,et al.  A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[66]  W. Filipowicz,et al.  Properties of the regulatory RNA-binding protein HuR and its role in controlling miRNA repression. , 2010, Advances in experimental medicine and biology.

[67]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[68]  O. Volpert,et al.  The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression , 2004, Breast Cancer Research and Treatment.

[69]  Tokichi Miyakawa,et al.  Ultraviolet B-induced skin angiogenesis is associated with a switch in the balance of vascular endothelial growth factor and thrombospondin-1 expression. , 2004, The Journal of investigative dermatology.

[70]  E. Fosslien Molecular pathology of cyclooxygenase-2 in neoplasia. , 2000, Annals of clinical and laboratory science.

[71]  R. Hynes,et al.  Thrombospondin-1 is a major activator of TGF-beta1 in vivo. , 1998, Cell.

[72]  J. Schelter,et al.  Molecular and Cellular Pathobiology p 53-Responsive miR-194 Inhibits Thrombospondin-1 and Promotes Angiogenesis in Colon Cancers , 2011 .